References Maier, C., Hartung, N., de Wiljes, J., Kloft, C., & Huisinga, W
These contraindications are not suggestions
1996 Jul;88(1):14-9
Methods We searched PubMed, Embase, Cochrane and ClinicalTrials.gov up until 27 October 2021 for randomised controlled trials with a duration of at least 12 weeks that compared once-weekly tirzepatide 5, 10 or 15 mg with placebo or other glucose-lowering drugs in adults with type 2 diabetes irrespective of their background glucose-lowering treatment
To gain a foothold in the market, they can only compete on price and distribution channels
You need to know about rare but serious adverse effects and how to recognize them